Peng Wei, Nan Zhang, Liu Yongping, Shen Hanchao, Lin Chuangan, Lin Li, Yuan Bangqing
Department of Orthopaedics, 309th Hospital of PLA, Beijing 100091, China.
Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Exp Mol Pathol. 2014 Oct;97(2):273-8. doi: 10.1016/j.yexmp.2014.06.001. Epub 2014 Jun 10.
Much evidence leads to the exploration of immunologic approaches for eliminating tumor cells. Cytoplasmic polyadenylation element binding protein 4 (CPEB4) is considered to be a novel therapeutical target for glioblastoma. In this study, we transduced DCs with CPEB4 to explore the immune response in vivo. We found that DCs transduced with recombinant adenovirus encoding CPEB4 could induce specific cytotoxic T lymphocytes (CTLs) to lyse glioma cells and augment the number of IFN-γ secreting T-cells in mice. In addition, the modified DCs could effectively protect mice from lethal challenges against glioma cells, reduce tumor growth and increase the mice life span. These results suggest that the DC transduced with CPEB4 may induce anti-tumor immunity against glioma cells and might be used as an efficient tumor vaccine in clinical applications.
大量证据促使人们探索消除肿瘤细胞的免疫方法。细胞质聚腺苷酸化元件结合蛋白4（CPEB4）被认为是胶质母细胞瘤的一个新的治疗靶点。在本研究中，我们用CPEB4转导树突状细胞（DCs）以探索体内免疫反应。我们发现，用编码CPEB4的重组腺病毒转导的DCs可诱导特异性细胞毒性T淋巴细胞（CTLs）裂解胶质瘤细胞，并增加小鼠体内分泌干扰素-γ的T细胞数量。此外，经修饰后的DCs可有效保护小鼠免受胶质瘤细胞的致命攻击，减少肿瘤生长并延长小鼠寿命。这些结果表明，用CPEB4转导的DCs可能诱导针对胶质瘤细胞的抗肿瘤免疫，并且在临床应用中可能用作有效的肿瘤疫苗。
